# FORM 4

longer subject to

Section 16. Form 4 or

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB 3235Number: 0287
Estimated average
burden hours per
response... 0.5

Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Respo	nses)								_		
1. Name and Addres MCKEY JOHN I	2. Issuer Name and Ticker or Trading Symbol iBioPharma, Inc. [IBPM.OB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
C/O IBIOPHARM INNOVATION V	3. Date of Earliest Transaction (Month/Day/Year) 02/13/2009					Officer (give title Other (specify below)					
NEWARK, DE 1	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Exect any	Deemed 3. ution Date, if Trans Code hth/Day/Year) (Instr			Acquired	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or Amount (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Report or directly or indirectly.		ach cla	ass of securition	es benefi	ciall	y owned					

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(e.g., puts, cans, warrants, options, convertible securities)															
Title of Derivative	2. Conversion		3A. Deemed Execution Date, if	4. Transac		5. Numb	er	6. Date Exer Expiration I		7. Title and of Underlyi		8. Price of Derivative	9. Number of Derivative	10. Ownership	11. Nature of Indirect
		(Month/Day/Year)				Derivati	ve	(Month/Day/Year)		Securities		Security			Beneficial
	Price of		(Month/Day/Year)			Securitie		`		(Instr. 3 and	14)	-			Ownership
l` í	Derivative		`	`		Acquire	d			`		` ′		Security:	(Instr. 4)
	Security					(A) or							Following	Direct (D)	, ,
						Dispose	d of						Reported	or Indirect	
					(D)				Transaction(s)	(I)					
						(Instr. 3,	, 4,						(Instr. 4)	(Instr. 4)	
				and 5)											
				Code	V	(A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 0.2	02/13/2009		A		60,000		(1)	02/13/2019	Common Stock	60,000	\$0	60,000	D	

#### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MCKEY JOHN D JR C/O IBIOPHARMA, INC. 9 INNOVATION WAY SUITE 100 NEWARK, DE 19711	X						

### **Signatures**

/s/ John D. McKey, Jr.	02/17/2009
Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in three equal annual installments beginning on February 13, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.